METHOD FOR PREOPERATIVE PREDICTION OF THE RISK OF RECURRENCE IN PATIENTS WITH STAGE T1 ENDOMETRIAL CANCER Russian patent published in 2021 - IPC G01N33/50 A61B5/00 

FIELD: oncology and molecular biology.

SUBSTANCE: invention relates to oncology and molecular biology. In the preoperative period, venous blood is examined by multicolor flow cytometry using monoclonal antibodies to EpCam, CD45, CD44, CD24, N-Cadherin labeled with various fluorochromes, and NucBlue Live cell stain ready probes reagent nuclear dye. Then determine the number of Epcam + CD45- (cells/ml of blood) (X1), the number of CTCs with the Epcam + CD45-CD44-CD24-Ncadherin + phenotype (cells/ml) (X2), the number of stem CTCs without Epcam expression on the membrane with the Epcam phenotype (m) -CD45-CD44 + CD24- (cells/ml) (X3); the number of atypical/hybrid forms of CTCs with the Epcam + CD45 + phenotype (cells/ml) (X4). Then the value of the regression equation Υ is calculated according to the original formula. At Υ≥0.5, a high is determined, and at Υ<0.5, a low risk of endometrial cancer recurrence is determined.

EFFECT: method allows to reduce invasiveness and increase the accuracy, sensitivity and specificity of the method by 87.5% and 96.7%, respectively.

1 cl, 2 tbl, 2 ex